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The Epstein-Barr virus (EBV) BamHI A transcripts are a family of transcripts that are differentially spliced
and can be detected in multiple EBV-associated malignancies. Several of the transcripts may encode proteins.
One transcript of interest, RK-BARF0, is proposed to encode a 279-amino-acid protein with a possible endo-
plasmic reticulum-targeting sequence. In this study, the properties of RK-BARF0 were examined through iden-
tification of cellular-interacting proteins through yeast two-hybrid analysis and characterization of its expres-
sion in EBV-infected cells and tumors. In addition to the interaction previously identified with cellular Notch,
it was determined that RK-BARF0 also bound cellular human I-mfa domain-containing protein (HIC), epi-
thelin, and scramblase. An interaction between RK-BARF0 and Notch or epithelin induced proteasome-depen-
dent degradation of Notch and epithelin but not of HIC or scramblase. Low levels of endogenous Notch ex-
pression in EBV-positive cell lines may correlate with RK-BARF0 expression. However, a screen of EBV-positive
cell lines and tumors with an affinity-purified -RK-BARF0 antiserum did not consistently detect RK-BARF0.
These data suggest that while RK-BARF0 may have important cellular functions during EBV infection, and
while the phenotype of EBV-positive cells suggest its expression, RK-BARF0 levels may be too low to detect.
Epstein-Barr virus (EBV) is associated with the develop-
ment of several epithelial and lymphoid malignancies, such as
nasopharyngeal carcinoma (NPC), gastric carcinoma, Hodgkin
lymphoma, endemic Burkitt’s lymphoma, and posttransplanta-
tion lymphoma (14, 20). In each malignancy, viral infection is
latent and each disease state is accompanied by a specific
pattern of latent viral gene expression. EBV encodes at least
nine latent viral proteins, including six nuclear proteins,
EBV nuclear antigens (EBNAs) EBNA1, EBNA2, EBNA3A,
EBNA3B, EBNA3C, and EBNALP, and three latent mem-
brane proteins (LMPs), LMP1, LMP2A, and LMP2B (14).
In Burkitt’s lymphoma, a type I lymphoid malignancy, only
EBNA1 is expressed. The malignancies NPC and Hodgkin
lymphoma have a type II pattern of gene expression, and the
viral proteins EBNA1, LMP1, and LMP2A are expressed (4, 7,
31). Posttransplantation lymphoma and lymphoblastoid cell
lines (LCLs) immortalized with EBV express all latent proteins
and, thus, have a type III pattern of gene expression.
In vitro studies have demonstrated that EBNA1, EBNA2,
EBNA3A, EBNA3C, and LMP1 are essential for B-lympho-
cyte immortalization (6, 13, 18, 19), while EBNA3B, LMP2A,
and LMP2B are dispensable (18, 27). In addition to the latent
proteins, a family of rightward transcripts from the BamHI A
region are abundantly expressed in several EBV-associated
malignancies and EBV-infected cell lines (2, 4, 5, 7, 9, 11, 21,
31). The BamHI A transcripts (also called BARTs or CSTs)
are differentially spliced and give rise to several different family
members that are 3 coterminal. Several of these transcripts
have open reading frames (ORFs) that possibly encode pro-
teins (21). RK103 (also called RPMS1) is proposed to encode
a nuclear protein that interacts with the cellular CSL family
[CBF1, Su(H), Lag-1] DNA-binding protein CBF1 (also called
RBPJ) and inhibits the activity of EBNA2 and Notch intra-
cellular fragment (NotchIC) (25, 33). RB2 (also called A73) is
proposed to encode a cytoplasmic protein that interacts with
the cellular receptor for activated C kinase (RACK) (25).
All of the BamHI A transcripts contain the BARF0 ORF
at their 3 ends, which potentially encodes a 174-amino-acid
protein. One cDNA cloned from the xenografted NPC, C15,
contains the BARF0 ORF extended at its 5 end, termed
RK-BARF0 (21). RK-BARF0 is proposed to encode a 279-
amino-acid protein with a highly hydrophobic N-terminal
region that resembles an endoplasmic reticulum (ER)-tar-
geting sequence (8, 21). A yeast two-hybrid analysis of the
RK-BARF0 ORF revealed that it binds unprocessed Notch1
and Notch4 and induces nuclear translocation of a portion of
full-length Notch, suggesting that the putative protein may be
responsible for modulating Notch signaling (17).
Other indirect evidence for RK-BARF0 includes the pres-
ence of a functional CTL epitope in RK-BARF0 and antibod-
ies against RK-BARF0 detected in the antisera of NPC pa-
tients (9, 16). Anti-BARF0 antisera can immunoprecipitate
unprocessed Notch from Raji cells, an EBV-positive cell line,
but not DG75 cells, an EBV-negative cell line, providing evi-
dence that RK-BARF0 is expressed in an EBV-positive Bur-
kitt’s LCL (17). However, antisera that was used to identify
what was thought to be RK-BARF0 in EBV-positive cell lines
and tumors (8) was subsequently shown to cross-react with
HLA DR  chain, which runs at the same molecular weight as
RK-BARF0 as determined by sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis (15, 23). In this study, additional
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cellular binding partners of the RK-BARF0 protein have been
identified to further characterize its function. The ability of
RK-BARF0 to degrade Notch and induce nuclear transloca-
tion was also employed for evidence of in vivo expression.
MATERIALS AND METHODS
Plasmid construction. Flag- and His-tagged RK-BARF0 as well as deletion
mutants RK-158 and RK-179 were cloned into pMEP4 (Invitrogen) as previously
described (17). Myc-tagged Notch4 was cloned into the pMEP4 vector as previ-
ously described (17). Epithelin precursor, scramblase, and HIC cDNA fragments
were amplified by Pfx PCR from a human lung cDNA library. Epithelin precur-
sor was cloned into pCDNA3 with three myc epitopes at the C terminus (In-
vitrogen). HIC and scramblase were cloned into pCDNA3 with three myc epi-
topes at the N terminus (Invitrogen). Myc-tagged epithelin was also subcloned
into the pMEP4 vector (Invitrogen).
Yeast two-hybrid analysis. The yeast two-hybrid analysis was performed as
previously described (17).
Cell culture, tumors, and transfections. COS-1 and H1299 cells were main-
tained in Dulbecco’s modified Eagle medium (DMEM) (Gibco) containing 10%
fetal bovine serum (Sigma) and antibiotics. BL30, BL30 B95-8, BL30 P3HR1,
BL41, BL41 B95-8, BL41 P3HR1, B95-8, BJAB, DG75, P3HR1, Raji, Jijoye,
Akata, Akata EG, and Akata 3F2 cells were maintained in RPMI 1640 (Gibco)
containing 10% fetal bovine serum and antibiotics. C15, C17, and C18 xe-
nografted nasopharyngeal tumors were passaged in nude mice as previously
described (3). DG75 and Raji cells stably transfected with myc-tagged Notch4 in
the pMEP4 vector were transfected by electroporation and selected with 200 g
of hygromycin B (Roche)/ml. COS-1 cells were transiently transfected with
RK-BARF0 using the Fugene6 (Roche) transfection reagent as instructed by the
manufacturer.
Cell extracts and Western blots. DG75 and Raji cells containing inducible
myc-tagged Notch4 or the pMEP4 vector were treated with 5 M CdCl2 for 16 h.
MG132-treated cells were treated at a concentration of 20 M or were treated
with dimethyl sulfoxide (DMSO) vehicle control for 8 h. Cell extracts were
prepared by lysing cells on ice for 30 min in lysis buffer {20 mM Tris-HCl (pH
7.8), 150 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% 3-[(3-cholamidopropyl)-
dimethylammonia]-1-propanesulfonate (CHAPS)} containing 1 mM phenyl-
methylsulfonyl fluoride (PMSF), 0.5 mM sodium orthovanadate, and 5 g of
aprotinin per ml. Cell lysates were clarified by centrifugation. Equal amounts of
protein were loaded onto SDS-PAGE gels and were transferred to Immobilon-P
(Millipore). Polyclonal -cMyc, -His, and -HA were used to detect respec-
tively tagged proteins (Santa Cruz). Polyclonal -Notch1 that recognizes both the
intracellular and extracellular portions of Notch1 was used to detect endogenous
Notch1 (Santa Cruz). --Actin was used as a loading control (Santa Cruz).
Corresponding horseradish peroxidase-conjugated secondary antibody was used
(-rabbit [Amersham Pharmacia] and -goat [DAKO]), and proteins were de-
tected with the Supersignal West Pico Chemiluminescence system (Pierce) fol-
lowed by exposure to X-ray film (Kodak).
Coimmunoprecipitation of RK-BARF0 and cellular proteins. myc-tagged
HIC, scramblase, and epithelin precursor were immunoprecipitated with FLAG-
tagged RK-BARF0 by using -FLAG M2 affinity gel (Sigma) overnight at 4°C.
The beads were then washed and proteins were recovered by boiling in SDS
sample buffer. Immunoprecipitations were then subjected to SDS-PAGE, trans-
ferred to Immobilon-P, and used for Western blot analysis.
Cell fractionation. Cells were lysed by incubation in a hypotonic buffer (20 mM
HEPES, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM dithiothreitol,
protease, and phosphatase inhibitor cocktails [Sigma]) for 15 min on ice followed
by addition of Nonidet P-40 to a final concentration of 1%. Nuclei were pelleted
by low-speed centrifugation at 1,000  g for 10 min at 4°C. The supernatant was
collected as the cytosolic fraction. The crude nuclear pellet was further purified
by using Optiprep (Sigma) reagent as directed by the manufacturer. Briefly,
crude nuclei were resuspended in a 25% solution of Optiprep and underlaid with
30 and 35% layers of Optiprep. The gradient was spun for 20 min at 10,000  g.
The band of nuclei was collected from the 30%–35% interface, washed, pelleted,
and lysed with nuclear extraction buffer (20 mM Tris [pH 8.0], 420 mM NaCl, 1.5
mM MgCl2, 0.2 mM EDTA, 25% glycerol, protease inhibitor cocktail [Sigma],
and phosphatase inhibitor cocktail [Sigma]) with the salt concentration adjusted
to 400 mM with 5 M NaCl. Insoluble nuclear material was pelleted at high speed
for 10 min.
Affinity purification of RK-BARF0 antisera. Anti-RK-BARF0 antisera were
produced by injecting peptides generated from the RK-BARF0 amino acid
sequence (8) (Immuno-Dynamics, Inc., La Jolla, Calif.). The antisera were af-
finity purified against glutathione S-transferase (GST)-fusion proteins immobi-
lized on glutathione beads. Briefly, Escherichia coli DH5 cells were heat shocked
with pGEX-2TK encoding GST-BARF0 or GST and the first 158 amino acids of
RK-BARF0 (GSTRK-158) (8). A 100-ml starter culture was grown from one
colony overnight at 37°C with vigorous shaking. The next morning, the culture
was diluted up to 1.1 liters and grown for an additional 2 h. Protein expression
was induced with 1 mM IPTG for 3.5 h. The bacteria was pelleted, washed with
1 phosphate-buffered saline (PBS), resuspended in 5 ml of 1 PBS, and frozen
overnight at 80°C. The bacteria were thawed and spiked with a protease in-
hibitor cocktail (Sigma), and a 5-l aliquot was run on an SDS-PAGE gel and
Coomassie stained to confirm induction. The bacteria were lysed by sonication,
spiked with Triton X-100 to a final concentration of 1%, shaken for 20 min at
4°C, and clarified by centrifugation. One-and-a-half milliliters of glutathione
Sepharose beads (Amersham Biosciences) were prepared by washing in PBS and
resuspending in PBS–Triton X-100. Clarified lysate was added to the resin and
was shaken for 2 h at 4°C. The beads were spun, washed three times with 200 mM
HEPES (pH 8.5), resuspended in 5 ml of cross-linking buffer (20 mM dimethyl
pimelimidate, 200 mM HEPES [pH 8.5]), and incubated with continuous mixing
for 1 h at 4°C. The beads were spun, and the cross-linking reaction was termi-
nated by incubation in 200 mM ethanolamine for 30 min at 4°C. The ethanol-
amine was removed by centrifugation, and the resin was resuspended in 200 mM
HEPES and loaded into a column. The noncovalently attached molecules were
removed by washing the column two times with glycine elution buffer (150 mM
NaCl, 200 mM glycine-HCl [pH 2.0]) and then washing them two times with
Tris-buffered saline (TBS). Before addition to the column, 2 ml of each serum
was diluted with 2 ml of TBS and then was filtered through a 2-m-pore-size
filter. The filtered antisera were applied to their appropriate columns. Serum
2161 was applied to the column with bound GSTRK-158, and serum 2157 was
applied to the column with bound GSTBARF0. Antiserum was loaded onto the
appropriate column a total of five times. The column was washed once with TBS,
once with wash buffer (500 mM NaCl, 20 mM Tris-HCl [pH 7.5], 0.1% Triton
X-100), and once more with TBS. The purified antisera were eluted in 500-l
fractions into 100-l aliquots of 1 M Tris-HCl (pH 8.5) with glycine elution
buffer. The fraction containing the purified antibody was dialyzed against 1
TBS with 10% glycerol.
RESULTS
RK-BARF0 binds cellular proteins. The yeast two-hybrid
method was used to identify cellular proteins that interact with
RK-BARF0 protein. The Gal4 DNA binding domain was fused
to an RK-BARF0 mutant with the highly hydrophobic 12 N-
terminal amino acids deleted. The GAL4-activating domain
was fused to a human lung cDNA library. Approximately 8.5 
105 transformants were tested on growth selection medium. As
published in an earlier report, RK-BARF0 bound Notch1, -3,
and -4 in two-hybrid and coimmunoprecipitation experiments.
Colonies that exhibited moderate to fast growth on selective
media were tested for -galactosidase (-gal) activity, and those
with moderate to intense -gal activity were sequenced. Through
the two-hybrid screen it was determined that, in addition to
Notch, RK-BARF0 bound human I-mfa domain-containing
protein (HIC), scramblase, and epithelin precursor (Table 1).
HIC was initially identified for its ability to modulate expres-
sion from viral and cellular promoters through an interaction
with positive transcription elongation factor b or human im-
munodeficiency virus (HIV) Tat (32). Epithelin precursor (also
TABLE 1. RK-BARF0 Yeast-two-hybrid results




Epithelin precursor..............................................................  (2–3)
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called acrogranin or granulin) is a growth factor implicated in
epithelial cell function that also binds HIV Tat (28). Scram-
blase is a nonspecific lipid translocase that is responsible for
disruption of plasma membrane asymmetry during apoptosis,
resulting in the presence of phosphatidyl serine in the outer
leaflet. The effects of these interactions have not yet been
characterized.
RK-BARF0 induces proteasome-dependent degradation of
Notch. Notch is an unusual family of transmembrane recep-
tors. Notch is synthesized as an unprocessed precursor in the
ER, processed in the trans-Golgi network (TGN) into two
fragments joined through disulfide bonds and eventually em-
bedded in the plasma membrane (1, 12). When the N-terminal
extracellular domain binds ligand such as Delta or Jagged, the
cytoplasmic domain is proteolytically processed, released from
the plasma membrane, and translocated to the nucleus, where
it affects transcription through and interaction with CBF1
(RBPJ) (24, 26).
It has been previously published that RK-BARF0 binds the
extracellular domain of Notch1, -3, and -4, and coexpression of
RK-BARF0 and Notch can induce nuclear translocation of
unprocessed Notch4 (17). RK-BARF0 also has an ER-target-
ing sequence and most likely binds unprocessed Notch in the
ER before it is processed into two fragments in the TGN. It
was also observed that Notch4 expression levels were reduced
when coexpressed with RK-BARF0 compared to levels when
expressed alone. Therefore, it was hypothesized that RK-
BARF0 may induce proteasome-dependent degradation of
Notch4. H1299 cells were transiently transfected with myc-
tagged Notch4 and His6-tagged RK-BARF0 or the first 158
amino acids of RK-BARF0 (RK-158), which cannot bind
Notch4, both under the control of an inducible promoter. Pro-
tein expression was induced with CdCl2, and cells were treated
with the proteasome inhibitor MG132 or DMSO vehicle
control. Unprocessed Notch4 levels were examined because
Notch4 was expressed exogenously in stable cell lines. Notch4
levels were reduced when coexpressed with RK-BARF0 as
determined by -myc Western blot, and this reduction was
blocked by MG132 treatment (Fig. 1A). Notch4 was not re-
duced when coexpressed with RK-158, which indicates that the
reduction was dependent upon the interaction between Notch
and RK-BARF0. To confirm that this phenomenon was not a
by-product of an exogenous expression system, RK-BARF0,
RK-158, and the first 179 amino acids of RK-BARF0 (RK-
179), which retains the ability to bind Notch, were stably trans-
fected into BJAB cells. Processed Notch levels were examined,
because an antibody directed against intracellular Notch was
used for Western blot analysis. Endogenous Notch1 levels
were reduced in cells expressing RK-BARF0 and were reduced
less dramatically in RK-179 cells (Fig. 1B). These data con-
firmed that the reduction is dependent on an interaction with
RK-BARF0 which induces proteasome-mediated degradation
of both endogenously and exogenously expressed Notch.
RK-BARF0 induces proteasome-dependent degradation of
epithelin precursor. To confirm that RK-BARF0 and epithelin
precursor interact in mammalian cells, Flag-His6-tagged RK-
BARF0, RK-158, or RK-179 was cotransfected with myc-
tagged epithelin precursor and used for coimmunoprecipita-
tions. Lysates were either directly loaded onto an SDS-PAGE
gel or immunoprecipitated with -FLAG beads for RK-
BARF0 and were used for Western blot analysis. RK-BARF0,
RK-158, and RK-179 were detected with -His antibody, and
epithelin precursor was detected with -myc. Abundant epi-
thelin precursor immunoprecipitated with RK-BARF0, but lit-
tle epithelin precursor immunoprecipitated with RK-179 and
RK-158 (Fig. 2A). This result was in contrast to those of
coimmunoprecipitation experiments with RK-BARF0 and
Notch, with the interaction mapping to amino acids 158 to 179
(17). Amino acids 158 to 179 were partially required, but the
interaction was not completely eliminated with RK-158 (Fig.
2A). However, like Notch4, epithelin precursor protein expres-
sion was reduced when coexpressed with RK-BARF0 but not
with RK-158, as determined by -myc Western blot (Fig. 2B).
Furthermore, this reduction in expression was inhibited by
MG132 treatment (Fig. 2B). As RK-158 does not efficiently
bind epithelin and did not induce degradation of epithelin,
these data suggest that an interaction between RK-BARF0
and epithelin is required for proteasome-induced degradation.
FIG. 1. RK-BARF0 induces proteasome-dependent degradation of Notch. (A) H1299 cells were transiently transfected with combinations of
myc-tagged Notch4 and full-length His6-tagged RK-BARF0 or a mutant encoding the first 158 amino acids of RK-BARF0 (RK-158), which cannot
bind Notch. Expression was induced with 5 M CdCl2, and the samples were treated with DMSO or 20 M MG132. Notch4 was detected by
immunoblot with -myc. (B) BJAB stable cells expressing full-length His6-tagged RK-BARF0, RK-158, or the first 179 amino acids of RK-BARF0
(RK-179) were induced with 5 M CdCl2 and immunoblotted with -His6 to detect RK-BARF0 (top panel) or -Notch1 to detect endogenous
Notch1 (bottom panel).
12850 THORNBURG ET AL. J. VIROL.
To ensure that RK-BARF0-induced degradation of cellular
proteins is specific for proteins that directly bind RK-BARF0,
His6-tagged RK-BARF0 or RK-158 was coexpressed with
myc-tagged epithelin or myc-tagged A20, which does not bind
RK-BARF0. RK-BARF0 was detected by Western blot using
-His, and epithelin precursor and A20 were detected with
-myc. Confirming the earlier data, epithelin precursor levels
were reduced when coexpressed with RK-BARF0 but not with
RK-158 (Fig. 2C). In contrast, A20 levels were not reduced by
coexpression of RK-BARF0 or RK-158, suggesting that RK-
BARF0-induced degradation was specific for bound cellu-
lar protein and not for the myc epitope tag or noninteracting
proteins.
RK-BARF0 binds HIC and scramblase but does not induce
proteasome-dependent degradation. To confirm the yeast two-
hybrid results, FLAG- and His6-tagged RK-BARF0, RK-158,
or RK-179 was coexpressed with either myc-tagged HIC or
scramblase and lysates were used for coimmunoprecipitation.
Lysates were either directly loaded onto an SDS-PAGE gel or
were immunoprecipitated for RK-BARF0 by using -FLAG
beads. When RK-BARF0 and HIC were coexpressed, myc-
tagged HIC coimmunoprecipitated with RK-BARF0 and RK-
179 but not with RK-158 (Fig. 3A), confirming the yeast two-
hybrid results. To examine the effect of RK-BARF0 expression
on degradation of HIC, myc-tagged HIC was coexpressed with
His6-tagged RK-BARF0 or RK-158 and cells were treated
with the proteasome inhibitor MG132. HIC levels were not
reduced when coexpressed with RK-BARF0 or RK-158 (Fig.
3B). Furthermore, levels of protein expression were un-
changed by treatment with MG132. When RK-BARF0 and
scramblase were coexpressed, myc-tagged scramblase also co-
immunoprecipitated with RK-BARF0 and RK-179 but not
with RK-158 (Fig. 4A). To examine the effect of RK-BARF0
expression on degradation of scramblase, myc-tagged scram-
FIG. 2. RK-BARF0 binds and induces proteasome-dependent deg-
radation of epithelin precursor. (A) H1299 cells transiently transfected
with Flag and His6-tagged RK-BARF0, RK-158, or RK-179 or with
epithelin precursor were induced with CdCl2. Lysates were directly
loaded onto an SDS-PAGE gel (left panel) or were immunoprecipi-
tated with -Flag (right panel). RK-BARF0 was detected with -His6,
and epithelin precursor was detected with -cMyc. (B) H1299 cells
transiently transfected with a combination of RK-BARF0 or RK-158
and epithelin precursor (Epi-P) were induced with 5 M CdCl2 and
treated with 20 M MG132 or DMSO control. Epithelin precursor was
detected by immunoblot with -cMyc. (C) H1299 cells transiently
transfected with RK-BARF0 or RK-158 and epithelin precursor
(Epi-P) or A20 were used for immunoblot. RK-BARF0 was detected
with -His6, and epithelin and A20 were detected with -cMyc. IP,
immunoprecipitation; WB, Western blot.
FIG. 3. RK-BARF0 binds HIC but does not induce proteasome-
dependent degradation. (A) Flag- and His6-tagged RK-BARF0, RK-
179, and RK-158 were transiently transfected into H1299 cells with
myc-tagged HIC. Lysates were directly loaded onto an SDS-PAGE gel
(left panel) or immunoprecipitated (IP) with -Flag (right panel).
RK-BARF0 was detected with -His6, and HIC was detected with
-cMyc. (B) RK-BARF0 and RK-158 were transiently transfected into
H1299 cells with HIC and were treated with 20 M MG132 to examine
degradation of HIC. HIC was detected with -cMyc.
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blase was coexpressed with His6-tagged RK-BARF0 or RK-
158 and cells were treated with the proteasome inhibitor
MG132. Scramblase levels were not reduced when coexpressed
with RK-BARF0 or RK-158 (Fig. 4B). In contrast to Notch
and epithelin precursor, expression of RK-BARF0 did not
induce proteasome-dependent degradation of HIC or scram-
blase. These data indicate that RK-BARF0 has specific effects
on cellular interacting proteins as it targets Notch and epithe-
lin for proteasome degradation, while the RK-BARF0 and
HIC-scramblase interaction may affect the function of the pro-
teins in other ways.
Phenotype of EBV-positive cells indicates presence of RK-
BARF0 protein. Definitive evidence for a protein encoded by
the RK-BARF0 transcript has been elusive. While a previous
publication detected a protein of approximately the same size
predicted for RK-BARF0 in only EBV-positive cells by using a
rabbit antisera raised against an antigenic peptide (8), subse-
quent publications indicated that the antiserum also detects
the HLA DR  chain, which is upregulated by EBV infection
and is approximately the same size as the predicted RK-
BARF0 (15, 23). Indirect evidence suggesting the existence of
the protein includes the point that antibodies directed against
RK-BARF0 are readily detectable in the antisera of NPC pa-
tients (9). Furthermore, -BARF0 serum can be used to im-
munoprecipitate transfected Notch4 from the EBV-positive
cell line Raji but not the EBV-negative cell line DG75 (17).
Based on the properties of RK-BARF0, the phenotypes of
EBV-positive and -negative cell lines were characterized to
evaluate the potential expression of RK-BARF0 protein in
vivo. As was demonstrated in Fig. 1, RK-BARF0 induces the
degradation of endogenous Notch1. Levels of Notch1 were
examined by Western blot analysis in EBV-positive and -neg-
ative cell lines to determine if a correlation exists between
Notch1 levels and possible RK-BARF0 expression. The cell
lines included the EBV-negative Burkitt’s lymphoma cell lines
BL30 and BL41 and their infected counterparts, BL30 B95-8,
BL30 P3HR1, BL41 B95-8, and BL41 P3HR1, which were
infected with the B95-8 or P3HR1 strain of EBV. The EBV-
negative B-cell lymphoma BJAB and Burkitt’s lymphoma,
DG75; EBV-positive, immortalized marmoset LCL B95-8; and
Burkitt’s lymphoma P3HR1 and Raji cell lines were also ex-
amined by Western Blot analysis. There was a strong correla-
tion between low levels of both unprocessed and processed
Notch1 and EBV infection (Fig. 5A). The two parental Bur-
kitt’s lymphoma cell lines BL30 and BL41 had relatively high
levels of Notch1, whereas their infected counterparts had rel-
atively low levels of Notch1 (Fig. 5A, left panel). The EBV-
negative cell line BJAB had high levels of both unprocessed
Notch1 and processed Notch1, whereas the EBV-negative cell
line DG75 had intermediate levels of unprocessed Notch1. The
EBV-positive cell line B95-8 also had an intermediate level of
unprocessed Notch1, and the EBV-positive cell lines P3HR1
FIG. 4. RK-BARF0 binds scramblase but does not induce protea-
some-dependent degradation. (A) Flag- and His6-tagged RK-BARF0,
RK-179, and RK-158 were transiently transfected into H1299 cells with
myc-tagged scramblase. Lysates were directly loaded onto an SDS-
PAGE gel (left panel) or were immunoprecipitated (IP) with -Flag
(right panel). RK-BARF0 was detected with -His6, and scramblase
was detected with -cMyc. (B) RK-BARF0 and RK-158 were coex-
pressed with scramblase and were treated with 20 M MG132 to
examine degradation of scramblase. Scramblase was detected with
-cMyc.
FIG. 5. Notch levels in EBV-positive and -negative cell lines. (A) A
series of EBV-positive and -negative cell lines were used for immuno-
blot analysis. -Notch1 was used to detect endogenous Notch1 (top
panel), and --actin was used as a loading control (bottom panel).
(B) DG75 and Raji cells stably expressing myc-tagged Notch4 were
fractionated into cytosolic and nuclear lysates and used for immuno-
blot analysis. -cMyc was used to detect Notch4.
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and Raji had very low levels of unprocessed and processed
Notch1 (Fig. 5A, right panel). Equal protein loading was con-
firmed by -actin Western blot analysis (Fig. 5A, bottom panel).
It has also been previously published that RK-BARF0 has
the unusual ability to induce nuclear accumulation of unproc-
essed Notch (17). Normally Notch is synthesized in the ER,
processed in the TGN, and embedded in the plasma mem-
brane. Upon ligand binding, only the intracellular portion
translocates to the nucleus, where it can affect transcription.
Full-length unprocessed Notch had never before been detected
in the nucleus. Using this information, the subcellular location
of exogenously expressed myc-tagged Notch4 was examined in
the EBV-negative cell line DG75 and compared to that of the
EBV-positive cell line Raji. Both cell lines were fractionated in
parallel and used for Western blot analysis. While both cell
lines show approximately equal levels of expression of Notch4,
Raji has dramatically higher levels of nuclear unprocessed
Notch4 (Fig. 5B). Because the ability to translocate unproc-
essed Notch4 to the nucleus is unique to RK-BARF0, this data
supports the hypothesis that RK-BARF0 is expressed in Raji
cells. While the presence of Notch4 in the nuclear fraction due
to cytosolic contamination could not be completely eliminated,
both sets of cell lines were fractionated in parallel and should
have approximately equal contamination. It is also possible
that additional genetic changes in the Raji lymphoma cell line
may induce nuclear accumulation of unprocessed Notch. How-
ever, unprocessed Notch has only been detected in the nucleus
through an interaction with RK-BARF0, suggesting that the
levels of unprocessed nuclear Notch4 are most likely signifi-
cant.
Antisera raised against RK-BARF0-specific peptides were
purified with GST fusion proteins immobilized on glutathione
beads. Two peptides from the putative RK-BARF0 protein
were synthesized and used to immunize rabbits to produce two
RK-BARF0 antisera. The RK-BARF0 amino acid sequence is
listed with the two peptide sequences underlined that were
used to immunize rabbits (Fig. 6A). Antiserum 2161 was used
previously to survey EBV-positive and -negative cells and tu-
FIG. 6. Purification of RK-BARF0 specific antisera. (A) The sequence of the peptides used to inoculate rabbits are underlined within the
RK-BARF0 amino acid sequence. The EBV coordinates corresponding to the B95-8 genome are indicated along with RK-BARF0 and BARF0
start sites, the RK-BARF0 splice site, its corresponding exons (Va and VIIb), and amino acid 158. (B) Lysates from DH5 expressing
GST-BARF0 and GST RK-158 were probed with 2157 and 2161 sera to confirm reactivity. (C) Serum 2157 was purified against immobilized
GST-BARF0, and serum 2161 was purified against immobilized GST-RK-158. Purified sera and column flowthrough (Flow Thru) were tested
against DG75, COS-1, and COS-1 RK-BARF0 cell extracts.
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mors and identified a protein of the predicted molecular
weight in the EBV-positive cell lines (8). However, subsequent
publications revealed that the antiserum also detected HLA
DR  chain, which is upregulated by EBV infection and is
approximately the same molecular weight as the predicted
molecular weight of RK-BARF0 (15, 23). In order to reduce
the likelihood of detecting cellular proteins with the RK-
BARF0 antisera, each antisera was affinity purified with GST-
BARF0 or GST-RK-158 fusion protein. The fusion proteins
were expressed in and purified from E. coli DH5. DH5
lysates were used for Western blot analysis with the antisera to
confirm fusion protein expression and reactivity to the antisera
(Fig. 6B). As expected, the antiserum 2157, made with the
more C-terminal peptide, reacted efficiently against GST-
BARF0 but not against GST-RK-158. Also, the antiserum
2161, made with the N-terminal peptide, reacted against both
GST-BARF0 and GST-RK-158. Serum 2161 reacted more
specifically with GST-RK-158, so GST-RK-158 was used to
affinity purify 2161 and GST-BARF0 was used to purify 2157.
Both antisera were purified against their fusion protein immo-
bilized on glutathione beads. Column flowthrough and puri-
fied antisera were used to probe Western blots with DG75,
COS-1, and COS-1 transiently transfected with His-tagged
RK-BARF0 cell lysates (Fig. 6C). DG75 cells should express
HLA DR  chain and, therefore, any HLA DR  chain should
be detected in these lysates. The flowthrough from both anti-
sera had multiple cross-reacting bands. Purified antisera had
dramatically fewer cross-reacting bands and readily detected
His6-tagged RK-BARF0. However, antiserum 2157 reacted
more strongly to RK-BARF0 and has not been shown to cross-
react with an HLA DR  chain. Therefore, 2157 was deter-
mined to be the more useful antiserum to survey EBV-positive
and -negative cell lines.
RK-BARF0 is not consistently detected in EBV-positive
cells. The newly purified antiserum, 2157, was used to detect
the putative RK-BARF0 protein in EBV-positive cell lines and
tumors by Western blot analysis. COS-1 cells and COS-1 cells
transiently transfected with His6-tagged RK-BARF0 were
used as negative and positive controls. Anti-His antibody was
used to detect His6-tagged RK-BARF0 (Fig. 7A, first two
lanes). Purified serum 2157 was used to detect His-tagged
RK-BARF0 and endogenous RK-BARF0. While serum 2157
detected His-tagged RK-BARF0 as efficiently as the -His
antibody, it did not detect any proteins of the correct molecular
weight in either EBV-positive cell line Akata or Akata EG or
in the passaged EBV-positive NPCs C15, C17, or C18 (Fig.
7A). Western blot analysis of the EBV-positive cell lines B95-8,
Jijoye, and Raji and the EBV-positive C15 NPC tumor also did
not consistently detect the putative RK-BARF0 protein (Fig.
7B). However, a protein that is the same size as is predicted for
BARF0 was detected approximately 50% of the time in the
B95-8 cell line (Fig. 7B).
Because RK-BARF0 can be nuclear through utilization of
the nuclear localization signal (NLS) from bound Notch, it was
possible that RK-BARF0 may be concentrated in the nucleus
of infected cells. EBV-positive NPC tumors were fractionated
into cytosolic and nuclear extracts and were used for Western
blot analysis with the purified 2157 serum. However, RK-
BARF0 protein was not detected in either cytosolic or nuclear
extracts of C15 or C17 in this immunoblot (Fig. 7C).
As RK-BARF0 has the ability to induce proteasome-depen-
dent degradation of Notch and epithelin, it was possible that in
the process of inducing proteasome-dependent degradation of
bound proteins RK-BARF0 itself may be degraded, making it
FIG. 7. RK-BARF0 is not detected in EBV-positive cell lines and
in tumors. The purified serum 2157 was used to screen multiple EBV-
positive and -negative cell lines and tumors. COS-1 cells expressing
His6-tagged RK-BARF0 were used as a positive control. The serum
was used to screen whole-cell lysates (A and B) and fractionated cell
lysates (C and D) as well as MG132-treated cells (D). C-term, C
terminal; WB, Western blot.
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difficult to detect. To test this hypothesis, EBV-negative cells
of DG75 and EBV-positive cells of Raji were treated with
MG132, fractionated, and subjected to Western blot analysis
with purified 2157 serum. In the nuclear fraction of MG132-
treated Raji cells, a band of approximately the correct molec-
ular weight was detected that was not present in DG75 cells
(Fig. 7D). However, the band was not detected every time the
experiment was repeated. Collectively, the sporadic appear-
ance of proteins corresponding to the size of BARF0 and
RK-BARF0 suggest that both proteins may be expressed in
vivo; however, they may be expressed at very low levels or may
be controlled by a yet-to-be-determined factor.
DISCUSSION
The data presented in this paper identify new cellular bind-
ing partners for the putative viral protein, RK-BARF0, and
establish the ability of RK-BARF0 to induce proteasome-de-
pendent degradation of Notch and epithelin precursor. The
low levels of Notch may be indicative of RK-BARF0 expres-
sion in EBV-positive cells. Western blot analysis using rabbit
antiserum raised against an RK-BARF0 C-terminal peptide
and affinity purified using a GST-BARF0 fusion protein strong-
ly detected exogenously expressed RK-BARF0 but could only
occasionally detect a band that possibly represents RK-BARF0
in EBV-positive cells. The antiserum also detected a band of
the same apparent molecular weight as BARF0 in B95-8 cells
and RK-BARF0 in nuclear extracts from Raji cells treated with
MG132, suggesting that it is possibly expressed at low levels
and may be processed by the proteasome.
The existence of multiple unique BamHI A transcripts in
many EBV-associated malignancies has been confirmed by a
variety of different techniques (2, 5, 21, 25, 29). Distinct splice
variants have been detected by RNase protection assay,
which indicates that RK-BARF0 is less abundant than RK103
(RPMS1) or RB2 (A73) (25). Conversely, reverse transcription-
PCR from size-specific bands of C15 mRNAs that hybridize to
BamHI A-specific probes indicate that RK-BARF0 and RB2
transcripts can be amplified from the most abundant mRNA
and therefore may be expressed at high levels in vivo (21).
However, the majority of RK-BARF0 transcripts lack a trans-
lation stop site while only a small minority of transcripts use a
stop site that is embedded within the polyadenylation site (21).
This would suggest that only a portion of RK-BARF0 tran-
scripts contain the entire ORF to make a protein product. The
low abundance of the RK-BARF0 splice variant and the un-
usual 3 processing also suggest that its protein product would
be expressed at low levels.
The data presented in this study indicate that RK-BARF0
can induce proteasome-dependent degradation of Notch and
epithelin precursor. Difficulty in detecting RK-BARF0 protein
consistently could be due to this function, as RK-BARF0 may
be degraded along with its binding partners. This hypothesis is
substantiated by detection of a protein of the correct molecu-
lar weight in Raji cells treated with the proteasome inhibitor
MG132 (Fig. 7D). Furthermore, using the ability of RK-
BARF0 to induce Notch degradation and nuclear transloca-
tion of unprocessed Notch, RK-BARF0 expression in EBV-
infected cells correlated with reduced levels of endogenous
Notch and unprocessed Notch subcellular localization. The
difficulties in detecting endogenous RK-BARF0 may reflect its
low abundance. RK-BARF0, RK103, and RB2 can all be epi-
tope tagged, efficiently expressed, and bind intriguing cellular
partners through exogenous expression. These abilities suggest
that they all have the capacity to function within a cell.
From a yeast two-hybrid screen it was determined that the
RK-BARF0 protein binds cellular Notch (17). During Notch
processing and signaling, Notch is processed in the TGN, is
embedded in the plasma membrane, and is cleaved at the
plasma membrane upon ligand binding. In addition, the intra-
cellular portion is released and translocated to the nucleus,
where it affects transcription. RK-BARF0 binds Notch prior to
processing in the ER and induces nuclear translocation of
full-length, unprocessed Notch. As a result of this interaction,
a portion of unprocessed Notch is translocated to the nucleus
(17) while most of the remaining Notch is degraded by the
proteasome. Nuclear unprocessed Notch has not been charac-
terized and may not be functional. Furthermore, reduction of
overall Notch protein should inhibit Notch signaling. Previous
studies have determined that RK103 (RPMS) binds CBF1,
another component of the Notch signaling pathway, and blocks
Notch signaling (25, 33). Coexpression of the two BamHI A
proteins could effectively launch a multipronged attack on
Notch signaling to diminish it. The Notch pathway regulates
development and cell fate decisions through control of diverse
mechanisms, such as proliferation, cell cycle arrest, differenti-
ation, cell survival, and apoptosis. Due to its diverse functions,
disruption of controlled Notch activation, either through con-
stitutive activation or through constitutive repression, could
promote transformation and oncogenesis (30). Notch appears
to act as an oncoprotein in the context of murine mammary
epithelium, Reed-Sternberg cells in Hodgkin lymphoma, and
anaplastic large-cell lymphoma (30). Notch also appears to act
as a tumor suppressor in keratinocytes and squamous cell car-
cinomas (30). Therefore, disruption of Notch signaling by the
BamHI A proteins could contribute to virus-induced oncogen-
esis.
The yeast two-hybrid screen also identified RK-BARF0-in-
teracting proteins HIC, epithelin, and scramblase. HIC was
initially identified through its ability to bind HIV Tat and
regulates expression from viral and cellular promoters. Epithe-
lin also binds HIV Tat and is involved in cellular growth.
Scramblase is a nonspecific lipid translocase and is responsible
for disruption of membrane asymmetry during apoptosis. In-
teractions between these cellular proteins and RK-BARF0
could affect a wide variety of cellular functions, including tran-
scription, cell growth, and apoptosis.
The BamHI A transcripts are not essential for B-lymphocyte
transformation. However, they were originally cloned from
NPC and therefore may contribute to the development of
epithelial malignancy. Primate epithelial cells have been im-
mortalized by using a cosmid clone from the BamHI A region
of EBV that contains none of the latent proteins considered
essential for B-lymphocyte transformation (10). Precedence
also exists for a nonessential EBV protein promoting transfor-
mation, as LMP2A, which is also not essential for B-lympho-
cyte transformation, was found to transform epithelial cells
through its activation of the phosphatidylinositol 3-kinase/Akt
pathway (22). Furthermore, in type II latency, such as in NPC,
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RK-BARF0 and RK103 may be able to compensate for the
absence of EBNA2 and its ability to modulate Notch signaling.
In summary, these data indicate that the RK-BARF0 pro-
tein has the capacity to function within a cell and that it may
affect important cellular proteins through direct interactions.
While the protein has proven to be difficult to detect, these
data suggest its expression.
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